Kornimate/medical-research-clean huggingface dataset:
lymph node dissection before or after cystectomy

Conditions: Bladder Cancer

Summary: the purpose of this study is to compare different ways of performing surgery for bladder cancer. specifically, the goal is to determine whether it is better to remove the lymph nodes before removing the bladder or after removing the bladder during radical cystectomy. the study aims to answer two main questions: * does the order of surgical steps during radical cystectomy affect the occurrence of complications after surgery? * does the order of surgical steps during radical cystectomy impact the duration of the operation and the number of lymph nodes removed? participants in the study will be randomly assigned to one of two groups. one group will undergo lymph node removal before bladder resection, while the other group will have lymph node removal after bladder resection during radical cystectomy. throughout their hospital stay and for 30 days following the operation, participants will be closely monitored for various factors including operative details, pathology results, and any complications that may arise.

lymph node dissection (lnd) is an integral part of radical cystectomy (rc) for bladder cancer. lnd provides important diagnostic and prognostic information, and according to most studies, is associated with therapeutic benefit. the optimal extent and template for lnd in bladder cancer remains to be established. currently, there are no specific recommendations regarding the sequence of lymph nodes removal and bladder resection during radical cystectomy, and the decision is based mainly on individual surgeon preference. the aim of the lboac pilot randomized trial is to evaluate the difference in intraoperative parameters and postoperative outcomes between patients undergoing lnd before bladder resection during rc and those undergoing lnd after bladder resection during rc. lboac is a pilot randomized controlled trial with two parallel groups. the primary objective of the trial is the comparison of complication rate within 30 postoperative days. secondary objectives of lboac include comparing lymph node yield and operative time between the two groups. data for will be collected using electronic case report forms (ecrfs) at baseline and within 30 days after the surgery. this pilot study is designed to test feasibility of, to support the refinements of the protocol and to aid in sample calculation that can be used for larger scale trial.

Eligibility criteria:
inclusion criteria: * patients undergoing radical cystectomy for bladder cancer in the department of urology university hospital in krakow exclusion criteria: * previous pelvic lymph node dissection

Keywords: bladder cancer muscle-invasive bladder cancer radical cystectomy lymph node dissection
an study of aripiprazole in the treatment of methamphetamine dependence

Conditions: Methamphetamine Dependence

Summary: methamphetamine substance use is common worldwide. no approved pharmacologic treatments for methamphetamine dependence exist. aripiprazole are second generation antipsychotics，but have different pharmacological effects of neurotransmitters.to determine whether mirtazapine would reduce methamphetamine use among mehtamphetamine addicts.

methods:a multiple-center, randomized, double-blind.

Eligibility criteria:
inclusion criteria: 1. patients,diagnostic and statistical manual of mental disorders 4thed. (dsm-iv) criteria for methamphetamine dependence. 2. must sign a information consent form. 3. required to provide detailed address and phone number exclusion criteria: 1. serious organic disease. 2. suicide ideation or hurt others. 3. taking antipsychotic within two weeks before. 4. drug allergy to risperidone or aripiprazole. 5. pregnancy and breastfeeding women.

Keywords: methamphetamine-associated psychosis aripiprazole
open-label, flexible-dose study to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizophrenia, bipolar i disorder, or autism spectrum disorder

Conditions: Schizophrenia; Bipolar I Disorder; Autism Spectrum Disorder (ASD)

Summary: the purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizophrenia, bipolar i disorder, or autism spectrum disorder (asd) and to establish the benefit-risk profile of long-term treatment in this population.


Eligibility criteria:
inclusion criteria: * participants with diagnostic and statistical manual of mental disorders, fifth edition text revision (dsm-5-tr) primary diagnosis of schizophrenia or bipolar i disorder, or autism spectrum disorder as confirmed by kiddie schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (k-sads-pl) at the screening visit 1 (for de novo subjects, or as previously confirmed in parent study for subjects who completed study 3112-301-001 or m21-465). * de novo participants must have normal physical examination findings, clinical laboratory test results, and electrocardiogram (ecg) results at screening visit 1. abnormal results must not be clinically significant as determined by the investigator. participants enrolling after completion of study m21-465 or 3112-301-001 have had monitoring of laboratory tests, physical examinations, and ecgs at the completion visit of the parent studies. * participant must have a caregiver (parent or legally authorized representative) who is willing and able to be responsible for safety monitoring of the participant, provide information about the participant's condition, oversee administration of study intervention, and accompany the participant to all study visits. exclusion criteria: * participants with dsm-5-tr diagnosis of major depressive disorder, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder due to another medical condition. participants with asd that is associated with rett disorder, fragile-x syndrome, or childhood disintegrative disorder. * prior dsm-5-tr diagnosis of intellectual disability (iq \< 70) for schizophrenia and bipolar i disorder participants. prior dsm-5-tr diagnosis of profound intellectual disability (iq \< 25) for asd participants. * participant has a condition or is in a situation, which, in the investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study.

Keywords: schizophrenia bipolar i disorder cariprazine autism spectrum disorder (asd)
effect of a nickel free diet and nickel sensitization on gerd patients.

Conditions: Gastroesophageal Reflux

Summary: there is little evidence on the effect of a nickel-free diet on gastroesophageal reflux disease (gerd). we hope to determine if a nickel-free diet improves gerd symptoms in patients with a nickel allergy by having patients complete a questionnaire on their gerd symptoms before and after initiation of 8 weeks on a nickel-free diet.


Eligibility criteria:
inclusion criteria: * age 18 years or older with a history of gerd * owns a phone with a camera * has access to or is willing to sign up for mychart * is symptomatic for gerd at time of visit as determined by a score of \>12 on the gerd health related quality of life (gerd-hrql) questionnaire. (patients that are currently taking a proton pump inhibitor (ppi) they must have been on the ppi for at least 3 months.) exclusion criteria: * less than 18 years of age * no not have access to mychart * are not willing to sign up for mychart * have taken an oral steroid within 4 weeks * have experienced a sunburn or had significant sun exposure within the last 4 weeks, or applied a topical steroid to the area that the past test will be applied (i.e. upper back or arm) in the last 4 weeks. no vulnerable populations will be included.

Keywords: nickel-free diet gerd gastroesophageal reflux
eslicarbazepine acetate (bia 2 093) as therapy for refractory partial seizures in children

Conditions: Partial Epilepsy in Children and Adolescents

Summary: the purpose of this study is to examine the efficacy and safety of eslicarbazepine acetate (bia 2-093) when given with other anti-epileptic drugs to treat children with partial seizures whose condition has not been controlled by other drug treatments.

partial epilepsy, the commonest form of epilepsy, is a difficult condition to treat with many patients continuing to have symptoms despite trying several medications. lack of efficacy and adverse effects are commonly associated with current anti-epileptic drugs. this study will examine the efficacy in addition to safety and tolerability of a new anti-epileptic drug, eslicarbazepine acetate (bia 2-093), as an adjunctive therapy for refractory partial seizures in children. the primary analysis variables are: * the responder rate (the proportion of patients with at least a 50% reduction in standardised seizure frequency) * the relative reduction in standardised seizure frequency

Eligibility criteria:
inclusion criteria: * girls of child-bearing potential have to follow reliable and medically acceptable contraceptive method throughout the study * diagnosis of epilepsy for at least 6 months prior to enrolment * at least 4 partial-onset seizures in the last month prior to enrolment despite stable therapy with adequate dosage of 1 or 2 aeds * at least 4 partial-onset seizures during each 4-week interval of the 8-week baseline period * previous treatment with three or more aeds, in their maximum tolerated doses, for at least one month, without seizure control * current treatment with 1 or 2 aeds (any except oxcarbazepine); if present, vagus nerve stimulation is considered an aed * stable dose regimen of aeds during the 8-week baseline period * cooperation and willingness to complete all aspects of the study, including hospitalisation if required * written informed consent to participate in the study in accordance with local legislation exclusion criteria: * primarily generalised seizures * baseline seizure frequency substantially different from usual seizure frequency * known progressive neurological disorders * history of status epilepticus within the 3 months prior to enrolment * seizures of non-epileptic origin * lennon-gastaut * west syndrome * major psychiatric disorders * previous treatment any study with eslicarbazepine acetate

Keywords: epilepsy partial refractory children adolescents adjunctive randomised double-blind placebo-controlled parallel-group
evaluation of the effectiveness of an alcohol based hand gel for the reduction of warts on the hands

Conditions: Papillomavirus Infections; Warts; Condylomata Acuminata; Epidermodysplasia Verruciformis

Summary: the objective is to conduct a pilot study to determine the effectiveness of purell vf481 to treat warts located on the hands.

* at least 5, but not more than 20 participants will be enrolled in the study. * each wart is randomly assigned a test product prior to the start of the study * warts are equally distributed between products so that an equal number of warts treated on each person. one (1) product will be assigned to each hand to minimize treatment confusion for the participants * the test product will be applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage. * subjects will log date and time of application and anything notable (such as changes in wart appearance or missed dose) in a log book. * measurement of wart (longest diameter) and photos taken at each visit by trained office medical assistants, lpns, pa-c or md. * time points for office visitation: baseline (0 weeks), 4 weeks, 8 weeks, 12 weeks

Eligibility criteria:
inclusion criteria: * patients with 2+ warts being seen at a dermatologist's office * 2 or more warts on the hands that are located at least 1 cm apart or on separate fingers * warts must have been present for at least 2 months * wart size must be between 2 mm-15 mm in diameter * participants must be in good general health * participants must be able to speak and read in english. * participant must be able to read and sign participant instruction sheet, and informed consent and authorization. * subjects must be able to understand and execute the instructions presented in pictorial form. exclusion criteria: * pregnancy (patients will be asked to verify using criteria of contraception, menstrual cycle, and pregnancy test, if necessary). * treatment of warts with other methods such as salicylic acid, etc., in the past 14 days. * known allergies to common topical antimicrobials or the individual ingredients in either test product. * participation in a clinical study in the past 7 days or participation in another clinical study * unwillingness to perform requirements of the study * any medical condition that should preclude participation in the study, at the discretion of the physician * missed ≥ 6 of the treatments in a 4 week study period
digital therapy in shoulder rehabilitation.

Conditions: Shoulder Pain

Summary: digital therapy may provides real time visual feedbacks. instrumented devices objectively quantify the patient's performance during rehabilitation and thus could be helpful for the personalization of the exercises. the interactive ball of this trial allows measuring both movement and pressure applied on it. therefore, the objectives of this study are: (i) to evaluate whether the use of a novel digital therapy gaming system was therapeutically relevant during shoulder rehabilitation; (ii) to understand whether the device was effective in improving patients' engagement in comparison to a control non-gaming rehabilitation program.


Eligibility criteria:
inclusion criteria: * impingement syndrome, capsulitis, tendon injuries, degenerative joint or tendon pathologies * pain between 2/10 and 8/10 on a visual analogue scale exclusion criteria: * post-surgical patients * inability to perform active exercises * peripheral neurological deficits * cervical-brachialgia * algodystrophy
patient journey in hospital with heart failure in turkish population

Conditions: Heart Failure

Summary: the purpose of this study is to compose a national database of the etiologies, clinical and demographic characteristics, using diagnostic tests, precipitating and risk factors, management of from intensive care unit or coronary care unit to hospital discharge, length of stay in the intensive care unit and hospital, in-hospital mortality and discharge medications of hospitalized acute heart failure patients in turkish population.

the etiologies, precipitating factors, demographics, clinical characteristics, management and outcome of patients admitted in hospital with acute heart failure in turkish population will be recorded.

Eligibility criteria:
inclusion criteria: * patients \>18 years olds * clinical diagnosis of acute heart failure * admitted to the participating hospitals exclusion criteria: * patients \<18 years old * patients with acute heart failure who are discharged from the emergency room without admission. * failure to obtain informed consent

Keywords: heart failure diagnosis management
a phase iv study of huazhi rougan granule in the treatment of non-alcoholic simple fatty liver

Conditions: Efficacy and Safety

Summary: an open label, single-arm, multicenter phase iv study; there was a 2-week screening period and a 12-week / 24-week treatment period


Eligibility criteria:
inclusion criteria: 1. ≥18 years old; 2. those who meet the diagnostic criteria of non-alcoholic simple fatty liver and traditional chinese medicine syndrome classification of damp-heat obstruction syndrome; 3. voluntarily sign informed consent; 4. liver-to-spleen ct ratio \< 1.0; the imaging findings of liver were consistent with the diagnostic criteria of diffuse fatty liver; 5. hba1c≤6.5%；alt、ast、tbil≤2×uln；gfr≥60（ml/min/1.73m2）. exclusion criteria: 1. fatty liver caused by chronic heart failure, malnutrition and pregnancy, encephalopathy fatty liver syndrome (reye syndrome), b-lipoprotein deficiency, localized fatty liver; fatty liver caused by diabetes, long-term use of hormones, enteritis, gastrointestinal postoperative chronic infection, etc.; small intestinal bypass surgery, hepatocyte toxicity injury, chronic febrile diseases such as tuberculosis, ulcerative nodules; 2. severe fatty liver with ascites, edema, hyponatremia and other suspected cirrhosis; hepatitis or cirrhosis caused by viruses, drug poisoning, immune diseases and other factors; 3. pregnant and lactating women, women of childbearing age who do not take effective contraceptive measures (such as condoms, hormonal contraceptives, intrauterine devices) or male subjects who do not want to use contraception;； 4. patient with serious primary cardiovascular disease, kidney disease and other serious diseases that affect survival; 5. patient with a history of cancer; 6. patient with hcv antibody, hiv antibody positive or hbsag positive and hbv-dna titer positive; 7. have a history of alcohol abuse (alcohol equivalent male≥30g/d, female ≥20g/d) or drug abuse； 8. allergic to the components of this drug；； 9. those who participated in other clinical investigators within 3 months prior to screening; 10. those who with a history of diabetes； 11. patients who had used the same traditional chinese medicine for the treatment of non-alcoholic simple fatty liver within 2 weeks before screening (except experimental drugs); 12. the investigators consider she/he inappropriate to participate in this study.
corevitas multiple sclerosis (ms) registry

Conditions: Multiple Sclerosis

Summary: this prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for ms in a cohort of patients cared for by neurologists across north america. secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.

the objective of the corevitas multiple sclerosis (ms) registry is to create a national cohort of patients with ms. data collected will be used to better characterize the natural history of the disease and to extensively evaluate the effectiveness and safety of medications approved for the treatment of ms. this will be done through the standardized collection of validated patient-reported outcomes (pro) and clinician-reported outcomes (clinro), the prevalence and incidence of comorbidities and adverse events, medication utilization patterns and patient productivity measures. the design is a prospective, non-interventional, observational registry for patients with ms under the care of a licensed neurologist. longitudinal follow-up data is collected from both patients and their treating neurologist (also known as "providers" for a corevitas registry study) every 6 months (+/- 30 days) during routine clinical encounters using corevitas registry forms. these forms collect data on patient demographics, disease duration, medical history (including all prior and current treatments for ms), smoking status, alcohol use, disease activity and severity, pain, as well as other clinician- and patient-reported outcomes, comorbidities and adverse events, infections, hospitalizations, and other targeted safety outcomes. after the enrollment visit, ms patients and physicians will complete the follow-up questionnaires during regularly scheduled clinical encounters. the goal is to collect data from patients and providers at six month intervals. adverse events may be volunteered spontaneously by the subject, or be discovered as a result of general questioning by the investigator. during all corevitas related visits with the investigator, subjects will be questioned regarding the occurrence of adverse events.

Eligibility criteria:
inclusion criteria: 1. has a diagnosis of ms at the time of enrollment. 2. age 18 years or older at the time of enrollment. 3. willing to provide personal information. 4. initiating (prescribed or starting) an eligible medication for the treatment of ms at the enrollment visit. exclusion criteria: 1) is participating or planning to participate in a double-blind randomized trial for an ms drug. note: concurrent participation in another observational registry or open-label phase 3b/4 trial is allowed.
a long-term extension study of roactemra/actemra (tocilizumab) in patients with early moderate to severe rheumatoid arthritis who completed study wa19926

Conditions: Rheumatoid Arthritis

Summary: this multicenter, open-label, single arm, long-term extension study will evaluate the safety and efficacy of roactemra/actemra (tocilizumab) in patients with early moderate to severe rheumatoid arthritis who completed the wa19926 core study. patients will receive roactemra/actemra 8 mg/kg intravenously every 4 weeks for up to 104 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * patients who complete their last wa19926 core study visit (week 104) and who may benefit from study drug treatment according to the investigator's assessment * no current or recent adverse event or laboratory finding preventing the use of the study drug dose of roactemra/actemra 8 mg/kg at baseline visit * receiving treatment on an outpatient basis * females of childbearing potential must agree to use at least one adequate method of contraception, including a method with a failure rate of \<1% per year, during the treatment period exclusion criteria: * pregnant or lactating women * patients who have prematurely withdrawn from the wa19926 core study for any reason * treatment with an investigational agent or cell-depleting therapies since the last administration of study drug in the wa19926 core study * immunization with a live/attenuated vaccine since the last administration of study drug in the wa19926 core study * diagnosis since last wa19926 visit (week 104) of rheumatic autoimmune disease other than rheumatoid arthritis * diagnosis since last wa19926 visit (week 104) of inflammatory joint disease other than rheumatoid arthritis * inadequate liver, hematologic or renal function * history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies * known active or history of recurrent infections * evidence of active malignant disease, malignancies within the previous 10 years (except for basal cell carcinoma of the skin that has been excised and cured), or breast cancer diagnosed within the previous 20 years * uncontrolled disease states, such as asthma or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids